Zárate A, Basurto L, Saucedo R

Language: Spanish
References: 6
Page: 172-175
PDF size: 88.37 Kb.

ABSTRACT

Akira Endo, a Japanese biochemist was awarded the Laskert Prize 2008 for biomedical research. In the early 1970’s Endo examined thousands of compounds isolated from fungi and eventually identified a potent cholesterol-lowering substance that antagonized HMG-CoA reductase, decreasing cholesterol biosynthesis. These studies led to the development of pharmacological agent, statin, which was efficient to decrease cholesterol levels in blood which in turn was beneficial for treatment of atheroesclerosis. The use of statins has become widely accepted as medical treatment of hypercholesterolemia and prevention of cardiovascular disease.

REFERENCES

1. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C et al. Cholesterol treatment trialists’ (CTT) collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective metaanalysis of data from 90,056 participants in 14 randomized trials of statins. Lancet 2005; 366: 1267-1278.

2. Shanes JG, Minadeo KN, Moret A, Groner M, Tabaie SA. Statin therapy in heart failure: prognostic effects and potential mechanisms. Am Heart J 2007; 154: 617-623.

3. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH et al. Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352: 20-28.

4. Calabro P, Yeh ET. The pleiotropic effects of statins. Curr Opin Cardiol 2005; 20: 541-546.

5. Tobert JA. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov 2003; 2: 517-526.

6. Goldstein JL, Brown MS. The low-density lipoprotein pathway and its relation to atherosclerosis. Annu Rev Biochem 1977; 46: 897-930.